C4 Therapeutics, Inc. (CCCC) Shareholder Equity
- 2026-06-30: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $12.00K; Additional Paid in Capital, Common StockUSD $1.04B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-444.00K.
- 2026-03-31: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $10.00K; Additional Paid in Capital, Common StockUSD $998.38M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-322.00K.
- 2025-12-31: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $9.00K; Additional Paid in Capital, Common StockUSD $995.22M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $50.00K.
- 2025-09-30: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $7.00K; Additional Paid in Capital, Common StockUSD $872.52M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $87.00K.
C4 Therapeutics, Inc. Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Preferred Stock, Value, Issued USD | Common Stock, Value, Issued USD | Additional Paid in Capital, Common Stock USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD | Adjustments to Additional Paid in Capital, Other USD |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $0.00 | $12.00K | $1.04B | $-444.00K | $-787.46M | $247.26M | 3 month · $3.04M | 3 month · $14.00K |
| 2026-03-31 | $0.00 | $10.00K | $998.38M | $-322.00K | $-763.82M | $234.25M | 3 month · $2.67M | 3 month · $28.00K |
| 2025-12-31 | $0.00 | $9.00K | $995.22M | $50.00K | $-738.69M | $256.59M | 12 month · $19.10M | 12 month · $103.00K |
| 2025-09-30 | $0.00 | $7.00K | $872.52M | $87.00K | $-718.21M | $154.41M | 3 month · $4.59M | 3 month · $27.00K |
| 2025-06-30 | $0.00 | $7.00K | $860.13M | $-30.00K | $-686.04M | $174.06M | 3 month · $4.99M | 3 month · $25.00K |
| 2025-03-31 | $0.00 | $7.00K | $855.11M | $43.00K | $-660.02M | $195.14M | 3 month · $5.51M | 3 month · $25.00K |
| 2024-12-31 | $0.00 | $7.00K | $849.62M | $53.00K | $-633.70M | $215.99M | 12 month · $29.66M | 12 month · $10.00K |
| 2024-09-30 | $0.00 | $7.00K | $841.32M | $455.00K | $-599.13M | $242.66M | 3 month · $8.83M | 3 month · $32.00K |
| 2024-06-30 | $0.00 | $7.00K | $821.95M | $-440.00K | $-574.46M | $247.06M | 3 month · $6.38M | 3 month · $36.00K |
| 2024-03-31 | $0.00 | $7.00K | $815.40M | $-380.00K | $-556.74M | $258.28M | 3 month · $6.21M | 3 month · $-16.00K |
| 2023-12-31 | $0.00 | $6.00K | $774.62M | $-127.00K | $-528.38M | $246.11M | 12 month · $27.23M | 12 month · $139.00K |
| 2023-09-30 | $0.00 | $5.00K | $710.55M | $-904.00K | $-493.63M | $216.02M | 3 month · $8.20M | 3 month · $36.00K |
| 2023-06-30 | $0.00 | $5.00K | $702.07M | $-1.77M | $-466.59M | $233.71M | 3 month · $6.42M | 3 month · $36.00K |
| 2023-03-31 | $0.00 | $5.00K | $695.61M | $-2.47M | $-430.67M | $262.47M | 3 month · $6.25M | 3 month · $32.00K |
| 2022-12-31 | $0.00 | $5.00K | $689.26M | $-4.14M | $-395.89M | $289.23M | 12 month · $29.86M | 12 month · $158.00K |
| 2022-09-30 | $0.00 | $5.00K | $682.29M | $-5.41M | $-358.70M | $318.18M | 3 month · $5.98M | 3 month · $31.00K |
| 2022-06-30 | $0.00 | $5.00K | $675.92M | $-4.58M | $-326.75M | $344.59M | 3 month · $8.11M | 3 month · $39.00K |
| 2022-03-31 | (m) | $5.00K | $667.51M | $-3.65M | $-299.33M | $364.53M | 3 month · $8.88M | 3 month · $59.00K |
| 2021-12-31 | $0.00 | $5.00K | $658.09M | $-775.00K | $-267.71M | $389.61M | 12 month · $21.34M | 12 month · $180.00K |
| 2021-09-30 | (m) | $5.00K | $650.99M | $-155.00K | $-252.06M | $398.78M | 3 month · $6.03M | 3 month · $222.00K |
| 2021-06-30 | (m) | $5.00K | $643.87M | $-69.00K | $-227.37M | $416.43M | 3 month · $5.17M | 3 month · $80.00K |
| 2021-03-31 | (m) | $4.00K | $468.59M | $-94.00K | $-204.79M | $263.70M | 3 month · $3.85M | 3 month · $-19.00K |
| 2020-12-31 | (m) | $4.00K | $464.60M | $13.00K | $-183.82M | $280.79M | 12 month · $3.43M | (m) |
| 2020-09-30 | (m) | $1.00K | $6.09M | $8.00K | $-162.03M | $-155.92M | 3 month · $436.00K 9 month · $713.00K | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | $-135.06M | 3 month · $161.00K | (m) |
| 2020-03-31 | (m) | (m) | (m) | (m) | (m) | $-124.53M | 3 month · $116.00K | (m) |
| 2019-12-31 | (m) | $1.00K | $5.53M | (m) | $-117.49M | $-111.96M | 12 month · $1.64M | (m) |
| 2019-09-30 | (m) | (m) | (m) | (m) | (m) | $-102.67M | 3 month · $627.00K 9 month · $913.00K | (m) |
| 2019-06-30 | (m) | (m) | (m) | (m) | (m) | $-93.41M | (m) | (m) |
| 2018-12-31 | (m) | (m) | (m) | (m) | (m) | $-79.75M | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |